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Emery–Dreifuss muscular dystrophyIn-frame mutations in nuclear lamin A/C lead to a multitude of tissue-speciﬁc degenerative diseases known
as the ‘laminopathies’. Previous studies have demonstrated that lamin A/C-null mouse ﬁbroblasts have
defects in cell polarisation, suggesting a role for lamin A/C in nucleo-cytoskeletal-cell surface cross-talk.
However, this has not been examined in patient ﬁbroblasts expressing modiﬁed forms of lamin A/C. Here, we
analysed skin ﬁbroblasts from 3 patients with Emery–Dreifuss muscular dystrophy and from 1 with dilated
cardiomyopathy. The emerin–lamin A/C interaction was impaired in each mutant cell line. Mutant cells
exhibited enhanced cell proliferation, collagen-dependent adhesion, larger numbers of ﬁlopodia and smaller
cell spread size, compared with control cells. Furthermore, cell migration, speed and polarization were
elevated. Mutant cells also showed an enhanced ability to contract collagen gels at early time points,
compared with control cells. Phosphotyrosine measurements during cell spreading indicated an initial
temporal lag in ERK1/2 activation in our mutant cells, followed by hyper-activation of ERK1/2 at 2 h post cell
attachment. Deregulated ERK1/2 activation is linked with cardiomyopathy, cell spreading and proliferation
defects. We conclude that a functional emerin–lamin A/C complex is required for cell spreading and
proliferation, possibly acting through ERK1/2 signalling.© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe LMNA gene is alternatively spliced to produce the two
intermediate ﬁlament proteins termed nuclear lamin A and C (lamin
A/C), which locate to the nuclear lamina, a ﬁbrous structure under-
lying the inner nuclear membrane (reviewed in [1]). Lamin A/C
interacts with many other nuclear proteins, including emerin
(encoded for by the EMD gene), SUN- and nesprin-family members
(reviewed in [2]). Mutations in either the LMNA or EMD genes result
in the neuromuscular disorder Emery–Dreifuss muscular dystrophy,
which is X-linked for EMD (X-EDMD; [3]) and autosomal (mainly
dominant) for the LMNA gene (A-EDMD; [4]). Intriguingly, the LMNA
gene is associated with an ever increasing number (currently tallying
16) of other tissue-speciﬁc degenerative diseases, which are collec-
tively termed the ‘laminopathies’ (reviewed in [5]). These can be split
broadly into two groups: i) neuromuscular disorders affecting directly
the skeletal muscle, cardiac muscle and peripheral nervous system
(e.g. A-EDMD, Limb-Girdle muscular dystrophy (LGMD1B), dilated
cardiomyopathy (DCM); ii) partial lipodystrophy syndromes (FPLD)
with or without developmental abnormalities and premature ageingfax: +44 (0)20 7848 6435.
ll rights reserved.such as Hutchison-Gilford Progeria Syndrome (HGPS). The lamino-
pathies display extensive clinical variability, with both intra- and
inter-familial variability observed within any one condition, suggest-
ing that the genetic background plays a large role on clinical
penetrance [6]. Moreover, although these diseases are clinically
penetrant in patients in the heterozygous form, mouse models need
to be homozygous to mimic the clinical phenotype [7–9].
Lamin A/C, emerin, and the LINC complex proteins SUN- and
nesprin-family members, form a variety of macro-protein complexes
at the nuclear envelope and together cross-link the nucleoskeleton to
the cytoskeleton. These protein complexes function to maintain both
nuclear architecture and cellular tensegrity [10–12]. Recently, it has
been shown that the LINC complex is also ‘hard-wired’ to the cell
surface. This involves the proteins giant nesprin-2 and nesprin-3α at
the outer nuclear membrane, interacting with micro- and intermedi-
ate ﬁlaments respectively, followed by a direct link to the cell adhesion
receptors, integrins, via talin and plectin respectively [11, 13, 14]. This
tight mechanical coupling created by the LINC complex allows for a
direct physical signalling pathway from cell surface-mediated events
to the nucleus and vice versa. Mutations in emerin, lamin A/C or
nesprin-1/2 result in nuclear morphology defects, by proteins being
either lost or mislocalised and to a disruption in chromatin–protein
interactions, that leads to downstream gene expression tissue-speciﬁc
effects [11, 15] For example, in skeletal muscle from EDMD patients
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and MyoD proteins are disrupted at the point of exit from the cell
cycle, delaying the onset of expression of genes involved in myogenic
differentiation [16, 17]. However, in the heart muscle, differentiation is
suppressed by inappropriate activation of the extracellular-regulated
kinase (ERK1/2) branch of the mitogen-activated protein kinase
pathway (MAPK) and downstream targets [18, 19], implicated
previously in both cardiomyopathy and cardiac conduction defects
[20, 21].
Cell adhesion and polarisation defects are also linked to the
absence of lamin A/C. lmna−/− MEFs (mouse embryonic ﬁbroblasts)
exhibit diminished ability to polarise at the edge of a wound [22–24],
whereas this was normal in MEFs from both Emd−/y mice and in a
mousemodel for HGPS (which in this instance expresses no lamin A/C
at the nuclear lamina [23]). Similarly, the activation of the small
GTPase RhoA, a key regulator of cytoskeletal dynamics, and cell–
substratum adhesion were decreased in both lmna−/− and HGPS
MEFs, but not in Emd−/y MEFs [23]. These differences were
attributed to both the degree of LINC complex disruption and the
absence of lamin A/C from the nuclear envelope, with the Emd−/y
mouse being least affected, since lamin A/C was correctly targeted to
the nuclear lamina. However, no studies have been reported on
possible cell surface effects in cells taken from laminopathy patients,
and/or in cells that express mutant forms of lamin A/C at the
nuclear lamina. This is an important point to address since there is
evidence suggesting lamin A/C-null mice models do not precisely
mimic the clinical situation e.g. desmin mislocalisation is not
observed in EDMD patient myoblasts [25], but is in cardiomyocytes
from lmna−/− mice [26].
Here, we set out to investigate whether nucleo-cytoskeletal-cell
surface links are also perturbed in dermal ﬁbroblasts taken from
laminopathy patients expressing missense lamin A/C mutations
associated with striated muscle diseases. We identiﬁed a reduction
in the emerin–lamin A/C afﬁnity alongside aberrant cell proliferation,
adhesion and spreading and temporal changes in ERK1/2 activation.
The severity of the molecular phenotype was mutation dependent.
Together, this data highlights cell surface defects can occur in
ﬁbroblasts expressing modiﬁed forms of lamin A/C, as well as in
cells null for lamin A/C. Furthermore, these defects arise directly from
an impaired emerin–lamin A/C interaction, which may in turn affect
LINC complex function.
2. Materials and methods
2.1. Patients and cells
All individuals gave their informed consent for cell studies, which
were approved by an institutional Ethics Review Board in Greifswald,
Germany (Protocol number BB 35/07, approve date, August 03, 2007).
Human dermal ﬁbroblasts from three A-EDMD patients with the
following lamin A/C mutations: R249Q (patient G-9666 in [27]),
R453W (patient Spo89 in [28]) and patient G-8626 in [27]), the
compound heterozygote R401C;T150HfsX5 (patient G-10877; [27],
case 2 in [29]) and one DCM patient: R377H (patient G-12625, which
we describe here for the ﬁrst time), were cultured as primary cell
lines. Clinical details of all of these patients except G-12625 are
described in [27, 29]. Patients were aged 25, 34, 16 and 37 respectively
at time of biopsy. Patient G-8626 died a few weeks after the cell
cultures were established of sudden cardiac death (SCD). Patient G-
10877 had inherited the R401C mutation from his mother, which was
an amino acid change classed as a genetic variant of unknown
signiﬁcance since she was clinically non-affected and the T150HfsX5
mutation (fsX5 means a c.447insC generating a stop codon at c.459X
predicted to produce a truncated protein) from his father, who
suffered SCD, without prior skeletal involvement. Patient G-12625
presented at age 26 with an episode of tachycardia. When lastexamined at age 33, the patient presented with DCM and cardiac
conduction defects without skeletal muscle involvement. Four other
family members with the same clinical phenotype died from SCD in
the 4th or 5th decade. However, other family members presented at a
few decades after the onset of skeletal weakness, but before the
cardiac complications, whereas other members developed no skeletal
muscle disease at all. Interestingly, the R377H mutation is a recurrent
mutation in the population and is associated with a range of other
laminopathies such as LGMD1B with cardiac involvement [30] and
adult onset proximal spinal muscular atrophy with cardiac involve-
ment [31]. This mutation also exhibits variable penetrance and
asymptomatic carriers have been reported [30, 32, 33].
Control dermal ﬁbroblast cell lines were taken from two females
(WT6000; aged 38 and WT6088; aged 55) and one male (WT6076;
aged 35) without any known disease. All cell lines were grown in α-
MEM (Gibco) supplemented with 10% FBS (Gibco) and 10 U/ml
penicillin and 50 mg/ml streptomycin. Experiments were performed
on cells between passage numbers 18 and 28.
2.2. Lamin A/C protein expression levels and interaction with emerin
To determine total lamin A and C protein expression levels in our
cell lines, lysates were prepared from cell samples of equal protein
concentrations, and immunoblotted for lamin A/C (N-18; 1:1000 or
Jol 5; 1:500), emerin (AP8; 1:2000) and as a loading control γ-tubulin
(Sigma; 1:5000). Cell samples of equal protein concentrationwere co-
immunoprecipitated in lysis buffer [34] for emerin–lamin A/C protein
complexes as described in [35]. Samples were immunoprecipitated
with anti-lamin A/C antibody N18 (1:100) and immunoblotted with
anti-emerin antibody AP8 (1:2000). Interactions were quantiﬁed
using densitometry (Gene Tools analysis software, version 3.00.22,
Synoptics Ltd) and expressed as a percentage of binding against total
amount of emerin extracted.
2.3. Cell proliferation assays
Sterile glass cover slips were coated with collagen (calf skin type I;
used at 0.1% (w/v); Sigma) in 24-well plates and air-dried for 2 h. Cells
were plated at 5000/well in α-MEM+10% FBS and ﬁxed at 1, 3, 6 and
10 days after plating. Cell proliferation was assessed and changes in
cell number quantiﬁed using the MTT [3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; Sigma No. M5655] metabolic
viability colorimetric assay according to the protocol supplied by
Sigma. To take into account cell size variation between cell lines,
standard curves for dye uptake were performed on each cell line.
Similarly, since the rate of cell adhesion (see below) also differed
between the cell lines, we expressed changes in proliferation as a fold
increase of the OD 570 nm value obtained on day 1 for each cell line.
Cell proliferationwas compared between the different cell lines over a
range of comparable passage numbers (18–28). Each proliferation
assay was repeated on three separate occasions, each time with
triplicate samples. A senescence-associated β-galactosidase staining
assay was used to determine the senescence rate of our cell lines [36].
2.4. Analysis of BrdU incorporation
To determine the proportion of cells in G0 of the cell cycle, sub-
conﬂuent cell cultures grown on collagen-covered cover slips in
complete α-MEM+10% FBS supplemented with 100 μM 5-bromo-2′-
deoxyuridine (BrdU) for 72 h. Cells were then ﬁxed in 4% (w/v)
paraformaldehyde (PFA) for 15 min with 2 M HCl treatment and
permeabilised in 0.2% (v/v) Triton X-100 before staining with anti-
BrdU antibody (1:100, Sigma) and counterstained with propidium
iodide (5 μg/ml) to observe total DNA content. The percentage of BrdU
(+) cells was determined for ∼500 cells in multiple ﬁelds in 4
independent experiments. Those cells negative for BrdU staining were
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the number of cells in S-phase, we ﬁrst calculated the time point the
cells entered S-phase. Cells were plated for 24 h, serum starved in α-
MEM containing antibiotics for 72 h to synchronise cells into G0
(when only 1% of cells incorporate BrdU), re-stimulated with 10% FBS
and pulse-labelled with 100 μM BrdU for 2 h at various times after re-
stimulation to determine the entry point into S-phase. Cell samples
were then ﬁxed, stained with anti-BrdU antibodies and analysed as
above.
2.5. Immunoﬂuorescent microscopy
Cells were ﬁxed in methanol at −20 °C and stained with anti-
emerin (AP8, 1:100; [37] or anti-lamin A/C (N-18, 1:100; Santa Cruz),
or ﬁxed in 4% PFA/0.2% (v/v) Triton X-100 for 15 min before staining
with anti-VASP (vasodilator-stimulated phosphoprotein, 1:100; Cell
Signalling technology) or ﬁxed in 4% (v/v) PFA for 15 min followed by
permeabilisation in 0.2% (v/v) Triton X-100 before staining for
integrin β1, α1, α2, (clone 4β7, 1:100; MAB1973, 1:250 and
MAB1950, 1:250; Chemicon, respectively), anti-phosphotyrosine
(clone 4G10, 1:500; Upstate Cell Signalling Solutions), talin (1:250,
Sigma) or paxillin (1:250, BD BioSciences). F-actin was labelled with
TRITC-phalloidin (1:500; Sigma). Secondary antibodies used were
Chemicon ﬂuorescent conjugates. Cover slips were mounted in
Vectorshield containing DAPI (Vectorlabs). Fluorescent images were
obtained using an Axiovert 200 M Zeiss inverted immunoﬂuorescent
microscope ﬁtted AxioCam HR camera using a Plan Neoﬂuar 40/0.57
Ph.2,±Optiva ×1.6 and analysed using AxioVision Rel.4.6 (Carl Zeiss
Inc) software. Confocal images were acquired on a Zeiss LSM 510Meta
confocal laser-scanning microscope using either ×25 or ×63 Plan
Neoﬂuar oil immersion objectives.
2.6. Rate of cell adhesion and collagen gel contraction assay
Cells were harvested, resuspended in α-MEM+10% FBS and
plated on either collagen I- or laminin-1 (Sigma, L2020) covered
glass cover slips at 1×103/well and immediately placed in an
incubator at 37 °C. At 10, 15, 30, 45, 60, 120 min after plating, non-
adherent cells were gently washed off with PBS. The remaining cells
were ﬁxed and stained with TRITC-phalloidin as described above to
ease cell visualisation. The total number of cells adhered to each cover
slip was counted under ×10 phase objective, each sample was
performed in triplicate, and the experiment repeated three times.
For collagen gel contraction assays the method was used as described
in [38]. Brieﬂy, 10,000 cells were mixed with collagen I (ﬁnal
concentration 1 mg/ml) in a total volume of 100 μl and added to
each well of a 96 well ﬂat-bottomed plate and allowed to set for
90 min at 37 °C. 100 μl of α-MEM+10% FBS was added per well, the
collagen plug carefully dislodged form the well sides with a needle
and the plate returned to 37 °C incubator. Phase-contrast images
(×0.11) of the collagen gels in their wells were collected over 24 h. 6
wells/cell line were used and the experiment repeated ﬁve times. The
degree of collagen contractionwas measured using the image analysis
programme, Image J, (http://rsb.info.nih.gov/ij/). In similar experi-
ments, collagen gels were ﬁxed in 0.1% glutaraldehyde at 2 and 24 h
after the initiation of gel contraction and immunostained for F-actin.
Z-stacks at 0.2 μm intervals were collected through the cells and a 3D
reconstruction as a projected image and as an AVI were collected on a
Leica confocal SP5 to examine cell morphological behaviour.
2.7. Cell spreading and shape analysis
Cells were harvested, resuspended in α-MEM+10% FBS and
plated at 5×104 cells/well of a 24-well plate containing collagen I-
coated glass cover slips and incubated in a 37 °C incubator. 3 cover
slips were collected at time points between 10min and 1 h and at 24 hafter plating, and three independent experiments were performed. At
collection, cover slips were gently washed in PBS, ﬁxed and stained for
focal adhesion proteins as described above. Cell samples were also
collected and immunoblotted for anti-total ERK1/2 (1:1000; Upstate
Cell Signalling Solutions) and anti-phospho-ERK1/2 (1:1000; Cell
Signalling technology). To calculate changes in cell shape during cell
spreading images of cells stained with anti-VASP were collected using
identical exposure settings in AxioVision Rel.4.6. For each cover slip, 5
ﬁelds where chosen at random and the area of 5 cells in each ﬁeld was
calculated (total of 25 cells/cover slip). Images were converted to 8 bit
greyscale Tiff ﬁles and imported into Mathematica 6.0 (Wolfram
Research, Champaign, IL, USA) where they were auto-levelled, de-
noised using a 5×5 low-pass ﬁlter, auto-levelled again and thre-
sholded to give black and white images in which white pixels
represented the footprint of the cell, whilst the black pixels
represented background. Further analysis in Mathematica 6.0 yielded
the following 2 cell shape parameters based on statistical moments
analysis: cell area (in μm2) and elongation (ratio of the longest axis to
the shortest axis expressed as a value of 2n, where n is the power you
need to raise to give that ratio) [39]. From the same anti-VASP stained
images, we also counted the number of ﬁlopodia/cell, where we
deﬁned a protrusion as projecting a minimum of 2 μm out from the
actin cortical ring, measured using the Image J programme. Similarly,
we calculated the percentage of the cell area occupied by focal
contacts (FCs) at each time point by converting our anti-VASP stained
images to 8-bit TIFF ﬁles and imported into Mathematica 6.0. These
were auto-levelled followed by de-noising using a 5×5 low-pass ﬁlter.
Next, images were subjected to a 25×25 high-pass ﬁlter to accentuate
regions containing pixels that had large differences in intensity
followed by further auto-levelling. The combination of the two ﬁlters
affects a band-pass ﬁlter that enhances the intensity of FCs, whilst
suppressing objects that are smaller or larger than these. The band-
pass ﬁltered image was then thresholded to give a binary image
consisting of white FCs on a black background. The Mathematica 6.0
programme from which this was derived can be seen in [40].
2.8. In vitro scratch and cell motility assays
Cells in α-MEM+10% FBS were plated at 1.5×105/well of a
collagen-coated 12 well plate, to achieve conﬂuent monolayers within
24 h of plating. A scratch was scored across the centre of each
monolayer with a plastic pipette tip. Pre-warmed α-MEM/25 mM
HEPES was added, the plate sealed and placed in a pre-heated
chamber (37 °C) on an inverted Axiovert 200 Zeiss microscope ﬁtted
with an Sensicam CCD camera (P.C. Cooke). Cells were allowed to
equilibrate and phase-contrast images were collected across the
wound under ×5 objective at 1 picture per 10min over 20 h. Similarly,
to examine single-cell motility behaviour, cells were plated at 2×104/
well, allowed to adhere for 15 min and images collected with ×5
phase objective every 3 min for 2 h. In the scratch assay at least 30
cells and in the cell motility assay at least 50 cells, from 3 and 6 wells
respectively were analysed for changes in mean speed and mean
persistence. Time-lapse image series in TIFF format were imported
into Mathematica 6.0 and the xy-co-ordinates of individual cells
determined at different time points using our own Mathematica 6.0
cell tracking programme. The persistence and speed of cell movement
was then determined from these co-ordinates. Persistence was
calculated by dividing the distance between the ﬁrst and last point,
i.e., distance as the crow ﬂies, by the actual distance covered by the cell
(by summing inter-frame distances across the whole time series).
Values tending towards one indicate cells moving in a straight line,
whereas values tending towards zero indicate random motion. Speed
was determined by dividing the inter-frame distances by the amount
of time between frames captured and is expressed in μm/hour. The
values presented represent the mean speed across all frames per time
series.
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All measurements are given as mean±SEM. The statistical
signiﬁcance was assessed using the two sample assuming equal
variance Student t-test, except for quantifying the immunoprecipita-
tion and pERK experiments where it was determined by performing
an ANOVA test followed by Dunnett's multiple comparison test.
3. Results
3.1. Lamin A/C expression and nuclear localisation
The dermal ﬁbroblasts expressing the R453W, R249Q or R401C;
T150HfsX5 (hereafter referred to as R401C) mutations used in this
study have been characterised previously between passages 1 and 11
for lamin A/C protein expression levels, nuclear antigen localisationand structure (Fig. 1A) [27]. Brieﬂy, they showed that ﬁbroblasts
expressing only the R401C and R453W mutations exhibited extreme
nuclear abnormalities with lamin A/C displaying a honeycomb or
intra-nuclei foci localisation, respectively. No nuclear abnormalities
were reported for the R249Q cell line. Although they also analysed a
cell line expressing the R377H mutation, this was from a different
patient to the one reported in the study here. Since we received the
cell lines at higher passage numbers (between 5 and 18) we re-
evaluated these parameters and characterised the cell line expressing
the R377Hmutation. Our ﬁndings for the nuclear localisation of lamin
A/C and emerin (data not shown) were consistent with that reported
by [27]. Our cell line expressing the R377Hmutation exhibited normal
nuclear architecture, in agreement with the cell line expressing the
same mutation reported in [27]. We also immunoblotted the cell lines
for emerin and lamin A/C using used two anti-lamin A/C antibodies;
N18 (epitope in ﬁrst 50 residues) and Jol 5 (epitopewithin the ﬁrst 117
residues) to counter the possibility of epitope masking arising from
the lamin A/C mutations skewing the antibody recognition. Both
antibodies gave the same immunoblotting results and those for N18 at
passage 22 are shown (Fig. 1B). We found that lamin A/C levels
remained stable as passage number increased, in both the normal
controls and mutants, but levels were consistently slightly less in the
R337H and R249Q mutant cell lines. Additionally, emerin was slightly
reduced in the R249Q cells. Unexpectedly, the R401C mutant cell line
expressed near normal levels of lamin A/C, as reported previously [27]
despite the prediction that the T150HfsX5 mutation severely
truncates the lamin A/C protein so that it is unlikely to be translated.
This suggests that protein expression from the allele carrying the
R401C mutation is upregulated.
3.2. Emerin–lamin A/C interaction is impaired
Emerin's binding site in lamin A/C spans residues 384–566, which
includes the R453W and R401C mutations [41], but there are data to
suggest that residues outside of this region additionally inﬂuence
emerin binding through uncharacterised secondary mechanisms [35,
42, 43]. To date, only one study has examined whether the emerin–
lamin A/C is impaired by LMNA mutations in vivo (R401C-alone and
R482L; [43]) and thus it is not known if the emerin–lamin A/C
interaction, is consistently affected by LMNA mutations. We immu-
noprecipitated our cell lines with anti-lamin A/C N18 antibody and
immunoblotted for emerin. Signiﬁcantly less emerinwas pulled down
with the mutant lamin A/C proteins than with our normal controls,
with the R401C being the most affected (17% less; Fig. 1C and D). WeFig. 1. Characterisation of cell lines used in this study. (A) Domain structure of human
lamin A indicating disease-causing mutations used in this study. Lamin A consists of a
central rod region of α-helical segments (coil 1a, 1b, 2a and 2b) and N- and C-terminal
globular tails. Numbers refer to amino acid residues in the primary sequence. Lamin C is
similar in structure, but is alternatively spliced at residue 566with a unique 6 residue tail
added. The positions of the mutations used in this study are marked by double-headed
arrows. Figure adapted from [35]. The emerin binding site is marked with a bold under-
line. (B) Immunoblot of the expression levels of lamin A/C and emerin in wild type and
mutant dermal ﬁbroblasts. 10 μg of cell lysates from non-synchronised cultured
ﬁbroblast cell lines all at passage 22 (3 controls,WT6000,WT6076,WT6088, 3 A-EDMD
patients and 1 DCM patient) were loaded on 10% SDS-PAGE gels and immunoblotted
with anti-lamin A/C antibody N18, anti-emerin antibody AP8 and anti-γ-tubulin
antibody as a protein loading control. (C) Co-immunoprecipitation of emerinwith lamin
A/C. Protein lysates of equal starting concentrationwere immunoprecipitatedwith anti-
lamin A/C N18 antibody. Eluted bound (B) and unbound (S) protein samples were
separated by 10% SDS-PAGE and immunoblotted for emerin. The experiment was
repeated 3 times and we show a representative example with control cell lineWT6000.
The lane marked ‘control’ is the co-immunoprecipitation performed only with the pre-
immune serum. (D) Binding fromthe 3 individual co-immunoprecipitation experiments
was quantiﬁed by densitometry (Gene Tools analysis software version 3.00.22,
Synoptics Ltd), averaged and shown as percentage bound of the total amount of emerin
present. The lane labelled ‘WTav’ represents an average value for the 3 control cell lines,
WT6000, WT6076 and WT6088. n=3; ⁎⁎=pb0.01 for mutants compared with WTav.
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interaction with emerin in vitro [35], whereas the R401C-alone
mutation has been reported to interact normally with emerin in vivo
[43]. It appears that mutations at residue R401 somehow reduce the
severe effect mutations at residue T150 cause. Interestingly, all of the
LMNA mutations used in this study are predicted to not affect lamin
dimer formation, but to perturb higher ﬁlament formation needed for
nuclear lamina structure and function [44]. Coupled with the lower
binding afﬁnity between emerin and lamin A/C, we propose that the
nuclear lamina-nuclear envelope link is functionally compromised in
the patient ﬁbroblasts used in this study.
3.3. LMNA mutations leading to EDMD/DCM increases cell proliferation
Cell hyper-proliferation is observed in the absence of lamin A/C
in lmna−/− MEFs [45, 46] and with the missense EDMD mutation
R453W expressed in a stable myoblast cell line [47]. However, in
patient dermal ﬁbroblasts homozygous for the LGMD1B-causing
mutation Y259X, which results in cells expressing no lamin A/C,
there is a decrease in cell growth [48, 49]. Clinically, the vast
majority of the laminopathies arise from in-frame LMNA mutations
affecting one allele, and thus a modiﬁed form of lamin A/C is
expressed alongside normal lamin A/C. To date, cell proliferation
has not been examined in cells expressing this genotype, and we
set out to investigate this. We calculated cell proliferation curvesFig. 2.Mutant cells exhibit increased proliferation. (A) Phase-contrast micrographs of each
collagen-covered cover slips were taken 1, 3, 6 and 10 days after seeding at equal cell density
the MTT assay. Standard curves were performed for each cell line to control for cell size diffe
shown as the fold increase in the OD 570 nm value for day 1 for each cell line. The data sho
triplicate. ‘WTav’ represents average values for the 3 control cell lines, WT6000, WT6076 a
(C) BrdU incorporation to determine the proportion of cells in GO and in S-phase. The dat
triplicate. ‘WTav’ represents average values for the 3 control cell lines, WT6000, WT6076for three controls and three EDMD- and one DCM-derived dermal
ﬁbroblast cell lines at comparable passage numbers (18–22). Phase-
contrast micrographs illustrate that all of the mutant cell lines
proliferated faster than all three controls (Fig. 2A). Proliferation was
quantiﬁed using the MTT assay as the fold increase over day 1 for
each cell line (Fig. 2B). The R401C cell line displayed the greatest
increase in proliferation followed by R453W and R249Q, with
R377H being only slightly elevated over the average for the 3
controls. Senescence (1.5–2% of all cells) was unchanged at
comparative passage numbers across all control and mutant cell
lines over this time course according to the senescence-associated
β-galactosidase activity assay (data not shown). Thus, changes in
senescence rates were not contributing to the differences in cell
proliferation.
We then examined whether the alterations in cell growth could be
attributed to a defect in cell cycle progression. We ﬁrst calculated the
point of entry into S-phase from G0whichwas 16 h for the control cell
lines and between 11 (R401) and 15 (R377H) h for mutant cell lines
(data not shown). BrdU positive cells were then counted at 2 h after
entry into S-phase. Consistent with the earlier S-phase entry time for
the mutant cell lines, a larger proportion of proliferating mutant cells
were in S-phase, compared with the three controls (Fig. 2C). Once
again the R401C mutant was the most affected, with 53% of cells in S-
phase, followed by R453W and R249Q, with R377H the least at 33%,
compared to an average for the 3 controls of 28% (Fig. 2C). Theseof our patient cell lines and 3 control cell lines (WT6000, WT6076, WT6088) grown on
. Bar; 100 μm. (B) Cell proliferationwas determined at 1, 3, 6 and 10 days after plating by
rences and variation in dye uptake between each cell line (data not shown). Results are
wn represent the average for three independent experiments, with each performed in
nd WT6088. n=3; pb0.05 for all mutant cell lines compared with the value for WTav.
a shown represent the average for three independent experiments each performed in
and WT6088. n=3; ⁎⁎=pb0.01.
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quiescent cells, since there was only a slight decrease in the
proportion of mutant cells in G0 compared to an average of the 3
controls (Fig. 2C). Together these results suggest a change in the
timing of entering S-phase contributes to changes in cell proliferation,
with the value of the change dependent on the speciﬁc LMNA
mutation.
3.4. Cell adhesion onto collagen is elevated by LMNA mutations
Cell proliferation is also dependent on growth regulatory effects
associated with cell adhesion and cell size. There are no prior reports
of EDMD/DCM cell lines being investigated in this manner. To initiate
such a study, we ﬁrst examined the rate of cell attachment onto either
collagen- or laminin-1-coated cover slips. Both themutant and control
cell lines adhered to laminin-1 at the same rate (data not shown),
where as all the mutant cell lines displayed an enhanced initial rate of
cell attachment over the three control cell lines onto collagen (Fig. 3).
This trend continued until about 45 min after plating, but by 1 h was
noticeably less marked. By 2 h the total number of attached cells was
similar for both mutant and control cell lines. The R401C cell line
attached the fastest (×2.05 over controls), followed by R453W and
R249Q, with R377H the slowest (×1.41 over controls), but was
statistically signiﬁcant over the controls. This direct correlation
between a particular LMNA mutation and the changes to both cell
adhesion and proliferation, suggest the LMNA mutations are func-
tionally responsible for these observed molecular phenotypes.
Changes in cell–substratum adhesion have also been reported in
lmna−/−MEFs, but here it was decreased [23]. Collectively these data
reinforce the theory that a functional nuclear lamina is required for
normal cell adhesion and this can be perturbed in a LMNA mutation-
speciﬁc manner.
3.5. LMNA mutations reduce cell spreading on collagen substrate
Cell adhesion rate is dependent on the rate of formation of focal
contacts (FCs). Cells modulate adhesion by controlling the surface
density, state of aggregation and activation of adhesion receptors. We
next examined the formation of FCs over 24 h, by imaging spreading
cells for a range of integrin subunits and components of FCs, F-actin,
emerin and lamin A/C. We observed no morphological alterations to
the nuclei or any re-distribution of emerin or lamin A/C during cell
adhesion and spreading in either mutant or control cell lines (data notFig. 3. Cell adhesion on to collagen. Cells were plated at 1×103cells/well on to collagen-
coated cover slips in the present of serum and ﬁxed at time intervals up to 2 h after
plating. The total number of cells adhered to each collagen-coated cover slip was
counted under ×10 phase objective. The data shown represent the average of three
independent experiments. ‘WTav’ represents average values for the 3 control cell lines,
WT6000, WT6076 and WT6088. n=3; ⁎⁎=pb0.01, ⁎=pb0.05 for the mutant cell
lines compared with the value for WTav.shown). Similarly, the distribution of the collagen receptor integrin
subunits α1, α2 and β1, the laminin-1 receptors integrin subunits α6
and α7 or the FC proteins talin and paxillin were not perturbed in the
mutant cell lines during cell adhesion (data not shown).
Following cell attachment, and in the absence of a chemotactic
stimulus, cells spread to achieve the cell mass required for cell
division.We next analysed the cell spreading phenomenon by staining
both control andmutant cells for VASP, which binds to and thus labels
the barbed ends of F-actin, FC components, lamellipodia and ﬁlopodia
tips. Anti-VASP stained cell images were band-pass ﬁltered, thre-
sholded to extract ﬂuorescent structures corresponding to FCs and
shown as a binary image alongside the corresponding anti-VASP
stained image (labelled as FC in Fig. 4A). Aberrant cell spreading
features were observed to affect 50–60% of the cell population for each
mutant cell line. We show cell images from the R401C and WT6000
cell lines in Fig. 4A and use the data collected to form Fig. 4A to
calculate the data presented in Fig. 4B–D. We ﬁrst calculated the
percentage of the total cell area covered by FCs. This demonstrated
that at each time point, approximately ×1.5 fold increase in cell area
was occupied by FCs in the mutant cells than in the controls (Fig. 4B).
This FC ‘crowding’ distorted observations of possible visual changes in
individual FC arrangement, morphology or numbers.
Next, we quantiﬁed the number of ﬁlopodia, cell area and cell
elongation changes during cell spreading. Two striking differences
were observed as early as 10 min after plating. Firstly, mutant cells
produced greater numbers of ﬁlopodia and few or no rufﬂes
compared to controls at each time point, a feature that persisted
until 1 h when ﬁlopodia levels normalised to that of the control
cells (Fig. 4C). Secondly, although cell area increased steadily with
spreading time for both control and R401C cells, at each time point
the total cell area was considerably less for the mutants than the
control cells and by 1 h was still only 55% of control levels (Fig.
4Di). The reduction in cell area of the R401C mutant was consistent
with its slightly lower elongation values compared to controls (Fig.
4 Dii). The other mutant cell lines also exhibited these changes in
cell spreading behaviour, but were not as severe as the R01C cell
line. It is noteworthy that by 24 h after plating, all of these
parameters were similar between the mutant and control cell lines,
suggesting that it is only early events in cell adhesion/spreading
that are disrupted. This may explain why cell spreading defects have
not been previously associated with LMNA mutations, since studies
have concentrated on cells plated for at least 24 h. Together, these
results suggest that cell adhesion and spreading are inﬂuenced by
nuclear antigen functionality, afﬁrming the theory that nucleo-
cytoskeletal links can be extended to include the cell adhesion
machinery at the plasma membrane.
3.6. Disorganised F-actin network and impaired phosphorylation of FC
components
We also stained spreading cells for F-actin and under confocal
microscopy this revealed that the F-actin network was slightly more
disorganised in the mutant cells compared with control cells, notably
with earlier production of cortical actin and stress ﬁbre retention at
24 h. We show cell images representing this ﬁnding from the R401C
and WT6000 cell lines in Fig. 5. Confocal microscopy conﬁrmed our
earlier ﬁndings of the mutant cells producing more ﬁlopodia. Previous
studies on lmna−/− MEFs also revealed minor disorganisation of the
microﬁlament, microtubule and intermediate ﬁlament networks,
most marked in the regions close to the perinuclear region [12]. It is
interesting to note that F-actin is also a binding partner of lamin A/C,
which binds through lamin A/C's C-terminal domain (residues 563–
646) [50]. Impairment of this interaction arising from secondary
effects of the LMNA mutations may contribute to the F-actin network
disorganisation and in turn compromise emerin–lamin A/C complex
function.
Fig. 4. Cell spreading on collagen. Cells from the control cell line WT6000 and the patient expressing the R401C mutation are illustrated in this ﬁgure. (A) Cover slips were
collected at times shown after cell plating in the presence of serum, ﬁxed and stained with anti-VASP antibody. Anti-VASP stained cell images were band-pass ﬁltered,
thresholded to extract ﬂuorescent structures corresponding to FC and shown as an auto-levelled binary image alongside the corresponding anti-VASP stained image (labelled as
‘FC’). Bar, 20 μm. (B) Images collected for the analysis of FC distribution in (A) were analysed for FC coverage. The total numbers of pixels representing FC in the thresholded
images were divided by the number of pixels representing the whole cell area. This is expressed as a percentage of cell area. n=25; ⁎⁎=pb0.01, ⁎=pb0.05 for the R401C
mutant cell line compared with the value for WT6000. (C) From the images captured in (A), we counted the number of ﬁlopodia (deﬁned as a pointed appendage projecting at
least 2 μm from the actin cortical ring) over the ﬁrst hour of spreading. n=25; ⁎⁎=pb0.01 for the R401C mutant cell line compared with the value for WT6000. (D) From the
images captured in (A) we calculated the cell area (i) and elongation (ii) over 24 h after cell plating. n=25; ⁎=pb0.05 for the R401C mutant cell line compared with the value
for WT6000.
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Fig. 5. Tyrosine phosphorylation during cell spreading. Cells from the control cell line WT6000 and the patient expressing the R401C mutation are illustrated in this ﬁgure. (A) Cover
slips were collected at 15 min, 30 min, 2 h and 24 h after cell plating, ﬁxed and stained with the anti-phosphotyrosine antibody (green) and TRITC-phalloidin for F-actin (red). Bar;
20 μm. (B) Cell samples were collected at 15 min, 30 min and 2 h after plating and immunoblotted for total ERK1/2, pERK1/2 and α-tubulin as a protein loading control. We show a
representative blot. (C) Immunoblot band intensities from the 3 independent experiments shown in (B) were quantiﬁed by densitometry (Gene Tools analysis software version
3.00.22, Synoptics Ltd), averaged and shown as ERK activity (pERK/total ERK). n=3; ⁎ ⁎=pb0.01 for the R401C mutant cell line compared with the value for WT6000.
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intracellular FC adapter proteins, promoting intermolecular SH-2-
phosphotyrosine interactions required for FC assembly [51]. Analysing
the phosphotyrosine level on FC components gives an indication of their
activation status. To examine for this, we immunostained our spreading
cells with an anti-phosphotyrosine antibody. Phosphotyrosine-positive
FC staining was less pronounced in the mutant cells than in the control
cells at 15 min post-attachment (Fig. 5A). Since it is already known that
deregulatedMAPK–ERK1/2 signalling precedes the development of the
cardiomyopathy in EDMD [18, 19] and that ERK1/2 signalling con-
tributes to the regulation of cell spreading [52], we next examined
ERK1/2's phosphorylation (pERK1/2) level during cell spreading.
Analysis with anti-phospho-p44/42 MAPK–ERK1/2 (T202/Y204) and
anti-total MAPK–ERK1/2 antibodies respectively identiﬁed a signiﬁcantly
reduced pERK1/2 at both 15 and 30 min after plating in our mutant cell
lines. At 2 h post-attachment, when cell spreading is completed, pERK1/2
was elevated in both control and mutant cell lines, but was signiﬁcantly
higher in the mutant compared to the control. Active pERK1/2 is
associated with cell proliferation and elevated pERK1/2 in laminopathy
affected cells or tissues has been reported previously [18, 19, 53]. We
hypothesise that a temporal delay in ERK1/2 activation is likely to be amajor contributing factor to the early reduction in cell area during cell
spreading in ﬁbroblasts expressing LMNA mutations.
3.7. Increased collagen gel contractility
Three-dimensional collagen gels allow for an in vivo approach to
study the ability of the cytoskeleton to provide the necessary tensional
force to counteract the mechanical load generated by the extracellular
matrix. Fibroblast cell lines were resuspended in a collagen gel matrix
then the set gel released from the sides of the plate, so as to remove the
tensional forces generated by the collagen.We calculated thepercentage
of gel contraction over time and found that the collagen gel contracted
faster when it contained mutant cells compared to control cells. A
representative experiment showing the gel contraction in a 96-well
plate for the R401C and WT6000 cell lines is shown in Fig. 6A.
Quantiﬁcation of gel areas demonstrated that the mutants exhibited an
accelerated rate of gel contraction at the early time points up to 4 h, and
then begun to tail off. By 10 h the gels containing themutant and control
cells contracted at a similar rate (Fig. 6B). We analysed the F-actin
network of the cells in the collagengels using confocalmicroscopy.Overt
changes in the basal actin cytoskeleton were observed between the
Fig. 6. Collagen gel contraction. (A) A collagen gel assay was performed in the presence
of serum as described in Materials and methods. Five separate experiments were
performed, each with 5 samples. Phase-contrast images (×0.11) were collected over a
24 h time course after plating. A representative example of the contraction gel 96-well
plate is shown at 4 and 24 h for the control cell line, WT6000 and the patient expressing
the R401C mutation. (B) From the collected images, the degree of collagen contraction
was calculated from the change in area of the collagen gel as a function of time, using
the image analysis programme, Image J. n=5; ⁎⁎=pb0.01 for the R401C mutant cell
line compared with the value for WT6000. Collagen plugs were ﬁxed at time points 2
and 24 h and the F-actin distribution (green) and nuclei (blue) distribution in the
individual cells were captured under confocal microscopy. Bar, 10 μm.
Table 1
Mean persistence and speed values from the scratch and cell motility assays.
WT6000 R401C
Scratch assay: n=33 n=39
Mean persistence 0.62±0.057 0.62±0.05
pb0.01
Mean speed 10.57±0.69 13.12±0.75
pb0.02
Cell motility assay: n=65 n=50
Mean persistence 0.57±0.065 0.56±0.058
pb0.01
Mean speed 6.89±0.26 8.19±0.40
pb0.02
818 L.J. Emerson et al. / Biochimica et Biophysica Acta 1792 (2009) 810–821mutant and control cells. 2 h after gel release, the control cells were still
reasonably rounded in shape with few ﬁlopodia projections, whereas
themajority of themutant cellswere larger andhad protrusions ofmany
ﬁne ﬁlopodia. (Fig. 6B, 2 h insets). The increase in early numbers of
ﬁlopodiawas consistentwith our cell spreading experiments performed
on a rigid substrate (Fig. 4A). By 24 h the control and mutant cells were
indistinguishable in cell shape, both appearing elongated with similar
numbers and shape of ﬁlopodia (Fig. 6B, 24 h insets). We conclude that
the collagen gel hyper-contractility observed in themutants arises from
their ability to formmore and earlier cell–substratum interactions in the
early stages of cell spreading, than our control cells.
3.8. Both polarized and random cell migration are elevated in the mutant
cell lines
We next investigated whether the LMNA mutations resulted in
cell migratory defects. Cells were imaged using phase-contrast time-
lapse microscopy and individual cells were tracked and analysed to
determine migration speed. Data demonstrates that mutant cells
migrated more rapidly than their normal control counterparts
(Table 1, Supplementary data). We also used a scratch assay to
determine if our mutant cells exhibited defective polarized motility.
Again the mutant cells exhibited a signiﬁcant increase in migration
speed over the normal controls. In both experiments the cell lines
exhibited similar mean persistence, indicating that the mutant cells
underwent corresponding polarised cell migratory trajectories to
normal controls (Table 1, Supplementary data). This is the ﬁrst
report examining the effect of LMNA mutations on random cell
migration. Previous reports examined only polarized cell migrationin scratch assays. MEFs from lmna−/− mice exhibited diminished
polarized cell migration, whereas MEFs from Emd−/y and HGPS
mice were unaffected, [22, 23]. Once again, these data reinforce the
theory that a functional nuclear lamina is required for cell surface-
mediated events, in this case cell migration, and that this can be
perturbed in a LMNA mutation-speciﬁc manner.
4. Discussion
4.1. Missense LMNA mutations affect cell cycle progression
It is well established that mutations in either the LMNA or EMD
genes alter cell cycle kinetics [37, 45–47, 54, 55]. For the LMNA gene,
most studies have been performed on the null phenotype and so it
is unclear if there are any mutation-speciﬁc effects. Here, we
demonstrate a signiﬁcant increase in cell proliferation associated
with EDMD-, but not DCM-causing mutations. Similarly, normal cell
cycle timing is associated with ﬁbroblasts from FPLD patients [43,
47], whereas a decrease in cell growth rate occurs in ﬁbroblasts
from HGPS patients [54]. Although only one each of a DCM, HGPS
and FPLD-derived cell lines have been analysed for cell proliferation
defects, collectively these ﬁndings infer laminopathy-speciﬁc effects.
The increase in cell numbers of mutant cells versus control cells
entering S-phase in our EDMD/DCM cell lines lie between those
reported for the lmna−/− MEFs and retinoblastoma-null MEFs [45],
whereas S-phase block developed with increasing passage number
in HGPS patient cells [54]. Johnson et al. attributed the S-phase
anomalies to a commensurate decrease in the percentage of cells in
both G1- and G2/M-phases and by inference, a similar mechanism
may also be occurring in the EDMD cell lines studied here.
Two mechanisms have been proposed to explain the increase in
cell proliferation associated with LMNA mutations. Firstly, defective
TGF-β1-Rb-SMAD signalling in lmna−/− MEFs was found to increase
their proliferation potential [46] and secondly, a failure of nuclear
envelope-Rb/MyoD interactions at the point of exit from the cell cycle
has been found to delay myogenic differentiation [16, 17]. However,
other signalling pathways that control cell proliferation may also be
involved. For instance, the MAPK–ERK1/2 signalling cascade regulates
cell proliferation as well as survival, growth and differentiation [56,
57]. Active ERK1/2 (which is phosphorylated; pERK1/2) is expressed
during cell proliferation and must be de-activated for cell differentia-
tion to occur. Both our patient and control cells exhibited an increase
in pERK1/2 activity after the completion of cell spreading, as expected
for cells entering the cell cycle. However, pERK1/2 was hyper-
activated in the mutant cell lines compared with the control cells.
This is consistent with the ﬁnding that hyper-activated pERK1/2 has
been found in cardiac tissue from lmna−/− mice and in HeLa
ﬁbroblasts and C2C12 myoblasts in which lamin A/C has been
knock-down by siRNA [18, 19, 53]. Perturbed ERK1/2 signalling is
therefore likely to contribute to the observed proliferation defect
associated with LMNA mutations.
819L.J. Emerson et al. / Biochimica et Biophysica Acta 1792 (2009) 810–8214.2. Aberrant cell adhesion, spreading and migration induced by LMNA
missense mutations
Integrin engagement stimulates the Ras-activated MAPK-ERK
cascade associated with cell growth and proliferation. Activated
ERK1/2 translocates to newly formed FCs [58] where it associates
with paxillin [59]. Cells deﬁcient in MEK1, the upstream activator of
ERK1/2, display increased cell adhesion and reduced cell spreading
[52] directly implicating ERK1 signalling in cell spreading. Active
ERK1/2 at FCs promotes the phosphorylation and thus activation of
myosin-light chain kinase (MLCK), resulting in increased actomyosin
contractility. This promotes FC disassembly an essential process to
allow cell spreading to proceed [60].
The results we present here implicate delayed ERK1/2 signalling
is contributing to the slower cell spreading phenotype observed in
our laminopathy patient cells. Others have shown that suppression
of ERK1/2 activity prevents its movement to the FCs [58], which in
turn would impede MLCK activation, ultimately reducing cell
spreading. However, we observed an increase in the initial stages
of contractility in the mutant cells during the initial stages of cell
spreading in collagen gels, suggesting earlier activation of MLCK.
Cells behave differently when spreading on rigid materials such as
collagen-coated cover slips, compared with spreading in softer
substrates such as collagen gels [61]. Therefore a direct comparison
of cell spreading phenotype between these substrata needs to be
interpreted with caution. Nevertheless, it is possible that the
enhanced activation of ERK1/2 we observed 2 h post-attachment of
cells spreading on collagen-covered cover slips, may occur earlier in
collagen gels, which would explain the earlier MLCK activation.
Notwithstanding this, many kinases regulate MLCK activity and
future work is needed to elucidate the exact mechanism behind
this.
A substrate-dependent effect was observed with respect to the
increase in cell adhesion observed in the mutant cell lines. Since the
integrin subunits involved in cell adhesion to both collagen or
laminin-1 substrate localised normally throughout cell spreading, it
is likely an inside-out signalling pathway is involved. We are currently
investigating this ﬁnding.
We also show here that both random and polarized cell
migration are elevated in our mutant cells compared to controls.
This is the ﬁrst time random cell migration has been shown to be
affected by LMNA mutations. The increased cell motility may arise,
at least in part, from the increased proliferative capacity of the
mutant cells. But taking our ﬁndings on increased cell motility with
both the increases in cell adhesion and FC coverage shown in Figs. 3
and 4, we can speculate that the mutant cells are likely to be
forming increased numbers of smaller FCs. This would result in an
initial increase in cell adhesion, but permit faster disassembly of the
FCs, elevating cell motility.
4.3. Lamin A/C modulates pERK1/2 activation through a direct
interaction
MAPK cascades are traditionally activated by either GPCR or RTK
signalling pathways and so it is not immediately obvious as to how
this could occur from a primary effect originating from a mutation in
nuclear lamin A/C. A recent publication sheds some light on this
dilemma. Lamin A/C is a binding partner of both pERK1/2 and the
transcription regulator c-Fos [62]. Lamin A/C sequesters c-Fos to the
insoluble nuclear fraction preventing it from activating AP1-mediated
transcription. Activated ERK1/2 binds to lamin A/C, releasing c-Fos
from lamin A/C, so that c-Fos can now be activated by pERK1/2.
Consistent with this mechanism, lmna−/− MEFs exhibit increased
AP1-mediated transcription compared with control cells [62]. The
nuclear lamina can thus act as a scaffold for components of theMAPK–
ERK1/2 pathway [62]. Taking the Gonzalez et al. results with the datawe present in this paper, we would like to propose that either the
presence of modiﬁed forms of lamin A/C or its total absence from the
nuclear lamina perturbs the nuclear lamina structure sufﬁciently to
directly affect both nuclear ERK signalling and delay ERK1/2
activation required for cell spreading.
In conclusion, our study has shown for the ﬁrst time that cells
from laminopathy patients exhibit perturbed cell surface signalling
as reported previously in the lamin A/C-null models. Our results
also suggest a correlation can be made between the genetic lesion
and how severely affected a particular molecular pathway is. The
R401C;T150HfsX5 mutation consistently disrupted the phenotypes
analysed in this paper signiﬁcantly more than the 3 other mutations
examined, particularly compared with the R377H mutation which
clinically resulted in DCM-alone in this instance. Finally, it is
interesting to note that mutations in either MEK1 or MEK2, give rise
to cardio-facio-cutaneous syndrome [63]. This is a developmental
delay disorder involving craniofacial, cardiac, hypotonia and ecto-
dermal abnormalities. Uniquely to disorders associated with the
Ras-pathway it is caused by missense mutations alone, as is the case
for the laminopathies. Exogenous expression of these mutations
produces hyper-activation of pERK1/2. Together these ﬁndings
highlight the importance of MAPK–ERK1/2 signalling in both cell
fate and subsequent tissue development.
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